Terms: = Sarcomas AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2
458 results:
1. FOXO3a deregulation in uterine smooth muscle tumors.
de Almeida TG; Ricci AR; Dos Anjos LG; Soares Junior JM; Maciel GAR; Baracat EC; Carvalho KC
Clinics (Sao Paulo); 2024; 79():100350. PubMed ID: 38636197
[TBL] [Abstract] [Full Text] [Related]
2. BRD4-targeting PROTACs Synergize With Chemotherapeutics Against Osteosarcoma Cell Lines.
Lang C; Stickler S; Rath B; Teufelsbauer M; Weigl L; Hohenegger M; Hamilton G
Anticancer Res; 2024 Mar; 44(3):971-980. PubMed ID: 38423674
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic impact of her2 biomarker levels in trastuzumab-treated early her2-positive breast cancer.
Rönnlund C; Sifakis EG; Schagerholm C; Yang Q; Karlsson E; Chen X; Foukakis T; Weidler J; Bates M; Fredriksson I; Robertson S; Hartman J
Breast Cancer Res; 2024 Feb; 26(1):24. PubMed ID: 38321542
[TBL] [Abstract] [Full Text] [Related]
4. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Piha-Paul SA; Xu B; Dumbrava EE; Fu S; Karp DD; Meric-Bernstam F; Hong DS; Rodon JA; Tsimberidou AM; Raghav K; Ajani JA; Conley AP; Mott F; Fan Y; Fan J; Peng P; Wang H; Ni S; Sun C; Qiang X; Levin WJ; Ngo B; Ru QC; Wu F; Javle MM
Oncologist; 2024 Apr; 29(4):e514-e525. PubMed ID: 38297981
[TBL] [Abstract] [Full Text] [Related]
5. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
6. A phase 2 trial of zanidatamab in her2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).
Lumish M; Chui MH; Zhou Q; Iasonos A; Sarasohn D; Cohen S; Friedman C; Grisham R; Konner J; Kyi C; Rubinstein M; Troso-Sandoval T; Aghajanian C; Makker V
Gynecol Oncol; 2024 Mar; 182():75-81. PubMed ID: 38262242
[TBL] [Abstract] [Full Text] [Related]
7. Establishment and Characterization of Cell Lines from Canine Metastatic Osteosarcoma.
Yang YT; Engleberg AI; Yuzbasiyan-Gurkan V
Cells; 2023 Dec; 13(1):. PubMed ID: 38201229
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy of Pyrotinib With/Without Trastuzumab in Treatment-Refractory, her2-Positive Metastatic Colorectal Cancer: Result From a Prospective Observational Study.
Zhou H; Lv M; Li W; Wang Y; Wu J; Liu Q; Liu T; Cui Y; Li Q
Clin Colorectal Cancer; 2024 Mar; 23(1):58-66. PubMed ID: 38177002
[TBL] [Abstract] [Full Text] [Related]
9. The Future of her2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results.
Nakano K
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069146
[TBL] [Abstract] [Full Text] [Related]
10. Molecular landscape of erbb2/her2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.
Nasioudis D; Gysler S; Latif N; Cory L; Giuntoli RL; Kim SH; Simpkins F; Martin L; Ko EM
Gynecol Oncol; 2024 Jan; 180():1-5. PubMed ID: 38029652
[TBL] [Abstract] [Full Text] [Related]
11. Genomic and Molecular Characteristics of Ovarian Carcinosarcoma.
Ramphal K; Hadfield MJ; Bandera CM; Hart J; Dizon DS
Am J Clin Oncol; 2023 Dec; 46(12):572-576. PubMed ID: 37986208
[TBL] [Abstract] [Full Text] [Related]
12. Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with her2 expression.
Kitadai R; Nishikawa T; Yoshida H; Mizoguchi C; Yamamoto K; Kato T; Yonemori K
J Gynecol Oncol; 2024 Mar; 35(2):e11. PubMed ID: 37914528
[TBL] [Abstract] [Full Text] [Related]
13. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With her2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
Meric-Bernstam F; Makker V; Oaknin A; Oh DY; Banerjee S; González-Martín A; Jung KH; Ługowska I; Manso L; Manzano A; Melichar B; Siena S; Stroyakovskiy D; Fielding A; Ma Y; Puvvada S; Shire N; Lee JY
J Clin Oncol; 2024 Jan; 42(1):47-58. PubMed ID: 37870536
[TBL] [Abstract] [Full Text] [Related]
14. Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets.
Høland M; Berg KCG; Eilertsen IA; Bjerkehagen B; Kolberg M; Boye K; Lingjærde OC; Guren TK; Mandahl N; van den Berg E; Palmerini E; Smeland S; Picci P; Mertens F; Sveen A; Lothe RA
EBioMedicine; 2023 Nov; 97():104829. PubMed ID: 37837931
[TBL] [Abstract] [Full Text] [Related]
15. Systematic literature review and meta-analysis of her2 amplification, overexpression, and positivity in colorectal cancer.
Singh H; Kang A; Bloudek L; Hsu LI; Corinna Palanca-Wessels M; Stecher M; Siadak M; Ng K
JNCI Cancer Spectr; 2024 Jan; 8(1):. PubMed ID: 37815820
[TBL] [Abstract] [Full Text] [Related]
16. Polypharmacology-based kinome screen identifies new regulators of KSHV reactivation.
Olson AT; Kang Y; Ladha AM; Zhu S; Lim CB; Nabet B; Lagunoff M; Gujral TS; Geballe AP
PLoS Pathog; 2023 Sep; 19(9):e1011169. PubMed ID: 37669313
[TBL] [Abstract] [Full Text] [Related]
17. erbb2 (her2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.
Heim C; Moser LM; Kreyenberg H; Bonig HB; Tonn T; Wels WS; Gradhand E; Ullrich E; Meister MT; Koerkamp MG; Holstege FCP; Drost J; Klusmann JH; Bader P; Merker M; Rettinger E
Front Immunol; 2023; 14():1228894. PubMed ID: 37662907
[TBL] [Abstract] [Full Text] [Related]
18. Clinicopathological and molecular analyses of uterine carcinosarcomas using next-generation sequencing: A single-center experience.
Erdogan EG; Yalta TD; Can N; Süt N; Taştekin E; Usta U; Puyan FÖ; Usturalı Keskin FE; Kurt BB
Indian J Pathol Microbiol; 2023; 66(3):449-455. PubMed ID: 37530323
[TBL] [Abstract] [Full Text] [Related]
19. Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
Saito A; Nishikawa T; Yoshida H; Mizoguchi C; Kitadai R; Yamamoto K; Yazaki S; Kojima Y; Ishikawa M; Kato T; Yonemori K
Gynecol Oncol; 2023 Sep; 176():115-121. PubMed ID: 37506533
[TBL] [Abstract] [Full Text] [Related]
20. Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast Cancer.
Weber WP; Matrai Z; Hayoz S; Tausch C; Henke G; Zimmermann F; Montagna G; Fitzal F; Gnant M; Ruhstaller T; Muenst S; Mueller A; Lelièvre L; Heil J; Knauer M; Egle D; Sávolt Á; Heidinger M; Kurzeder C; ; Zwahlen DR; Gruber G; Ackerknecht M; Kuemmel S; Bjelic-Radisic V; Smanykó V; Vrieling C; Satler R; Hagen D; Becciolini C; Bucher S; Simonson C; Fehr PM; Gabriel N; Maráz R; Sarlos D; Dedes KJ; Leo C; Berclaz G; Fansa H; Hager C; Reisenberger K; Singer CF; Loibl S; Winkler J; Lam GT; Fehr MK; Kohlik M; Clerc K; Ostapenko V; Maggi N; Schulz A; Andreozzi M; Goldschmidt M; Saccilotto R; Markellou P
JAMA Surg; 2023 Oct; 158(10):1013-1021. PubMed ID: 37466971
[TBL] [Abstract] [Full Text] [Related]
[Next]
